Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones

Alfonso Quintás-Cardama, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Several tyrosine kinase inhibitors (TKIs) are currently under development for the treatment of patients with chronic myelogenous leukemia (CML) resistant or intolerant of imatinib therapy, including nilotinib, dasatinib, and bosutinib. The current paradigm of TKI therapy involves a sequential use of these compounds, with imatinib invariably used as frontline therapy followed by either dasatinib or nilotinib on an empiric basis. A more sensible approach to this sequence is the selection of the TKI best suited to overcome the resistance conferred by BCR-ABL1 mutations detected at each time-point. As more TKIs are becoming available, the management of patients with CML will require degree of "finesse" to better match each patient with the best TKI available. This match is best made based on available in vitro data regarding the activity of each agent against each specific mutation. The case herein reported supports such strategy.

Original languageEnglish (US)
Pages (from-to)1313-1316
Number of pages4
JournalLeukemia Research
Volume32
Issue number8
DOIs
StatePublished - Aug 1 2008
Externally publishedYes

Fingerprint

Protein-Tyrosine Kinases
Clone Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
Mutation
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Imatinib Mesylate
Dasatinib

Keywords

  • BCR-ABL1
  • Bosutinib
  • Clones
  • CML
  • Imatinib
  • Nilotinib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones. / Quintás-Cardama, Alfonso; Cortes, Jorge.

In: Leukemia Research, Vol. 32, No. 8, 01.08.2008, p. 1313-1316.

Research output: Contribution to journalArticle

@article{0349a5c49a474cf3af7410a0e55c9ec9,
title = "Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones",
abstract = "Several tyrosine kinase inhibitors (TKIs) are currently under development for the treatment of patients with chronic myelogenous leukemia (CML) resistant or intolerant of imatinib therapy, including nilotinib, dasatinib, and bosutinib. The current paradigm of TKI therapy involves a sequential use of these compounds, with imatinib invariably used as frontline therapy followed by either dasatinib or nilotinib on an empiric basis. A more sensible approach to this sequence is the selection of the TKI best suited to overcome the resistance conferred by BCR-ABL1 mutations detected at each time-point. As more TKIs are becoming available, the management of patients with CML will require degree of {"}finesse{"} to better match each patient with the best TKI available. This match is best made based on available in vitro data regarding the activity of each agent against each specific mutation. The case herein reported supports such strategy.",
keywords = "BCR-ABL1, Bosutinib, Clones, CML, Imatinib, Nilotinib",
author = "Alfonso Quint{\'a}s-Cardama and Jorge Cortes",
year = "2008",
month = "8",
day = "1",
doi = "10.1016/j.leukres.2007.12.006",
language = "English (US)",
volume = "32",
pages = "1313--1316",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones

AU - Quintás-Cardama, Alfonso

AU - Cortes, Jorge

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Several tyrosine kinase inhibitors (TKIs) are currently under development for the treatment of patients with chronic myelogenous leukemia (CML) resistant or intolerant of imatinib therapy, including nilotinib, dasatinib, and bosutinib. The current paradigm of TKI therapy involves a sequential use of these compounds, with imatinib invariably used as frontline therapy followed by either dasatinib or nilotinib on an empiric basis. A more sensible approach to this sequence is the selection of the TKI best suited to overcome the resistance conferred by BCR-ABL1 mutations detected at each time-point. As more TKIs are becoming available, the management of patients with CML will require degree of "finesse" to better match each patient with the best TKI available. This match is best made based on available in vitro data regarding the activity of each agent against each specific mutation. The case herein reported supports such strategy.

AB - Several tyrosine kinase inhibitors (TKIs) are currently under development for the treatment of patients with chronic myelogenous leukemia (CML) resistant or intolerant of imatinib therapy, including nilotinib, dasatinib, and bosutinib. The current paradigm of TKI therapy involves a sequential use of these compounds, with imatinib invariably used as frontline therapy followed by either dasatinib or nilotinib on an empiric basis. A more sensible approach to this sequence is the selection of the TKI best suited to overcome the resistance conferred by BCR-ABL1 mutations detected at each time-point. As more TKIs are becoming available, the management of patients with CML will require degree of "finesse" to better match each patient with the best TKI available. This match is best made based on available in vitro data regarding the activity of each agent against each specific mutation. The case herein reported supports such strategy.

KW - BCR-ABL1

KW - Bosutinib

KW - Clones

KW - CML

KW - Imatinib

KW - Nilotinib

UR - http://www.scopus.com/inward/record.url?scp=42749085070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42749085070&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2007.12.006

DO - 10.1016/j.leukres.2007.12.006

M3 - Article

C2 - 18242697

AN - SCOPUS:42749085070

VL - 32

SP - 1313

EP - 1316

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -